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Chapter 5 Low-frequency and rare DNA sequence variants associated with primary sclerosing cholangitis susceptibility. IBD is a complex disease, meaning that its aetiology is multifactorial: genetic, epigenetic, microbiome and environmental factors interact and give rise to the disease.
Environmental factors like smoking, medication, appendectomy and diet have been implicated to play an role in the pathogenesis of IBD.
Over the last few years, the field of human genetics has seen an enormous gain of knowledge due to the development of high-throughput techniques, growing cohorts and new methods of analysis. IBD is one of the complex traits that have been extensively studied. At the start of this thesis project in 2010, 99 genetic risk loci for IBD had been identified, making it the most successfully Genome Wide Association (GWA) studied immune-mediated disease. GWAS typically ascertain at least 300.000 common single nucleotide polymorphisms (SNPs) throughout the genome, and for each of these variants the association is tested for the disease versus healthy controls. Because of the large number of genetic markers and statistical tests performed, strict statistical thresholds (P < 5 x 10 showed nominal evidence of replication (P < 0.05).
A number of PSC GWAS and large-scale genotyping studies have been performed with the latest immunochip-based study of nearly ~3500 subjects, extending the number of identified risk loci to 24.
Because of the highly correlated nature (so-called linkage disequilibrium) of human genetic polymorphisms, association signals often span broad genomic regions including multiple genes and transcribed sequences. So far, it has often been difficult to assign the likely "causal gene" driving the association signal. GWAS have typically been focussed on common SNPs with a high prevalence in the general population (SNPs with minor allele frequency (MAF) above 5%). However low frequency (minor allele frequency (MAF) between 1% and 5%) and rare (MAF < 1%) variants of higher effects (ie, high odds ratios) could also explain a substantial fraction of common complex diseases. In order to ascertain these low frequency and rare variants, sequencing of known genetic risk loci, 
Outline of the thesis
This thesis addresses three topics in IBD genetics I. Identifying additional common risk variants for inflammatory bowel disease II. Identification and exploring the role of rare variants in complex diseases
III. Translation of genetic variants into clinical practice
In Chapter 1, we give an overview of the clinical picture of IBD. We describe how the IBD genetic risk loci were identified by high-throughput genotyping technologies and the overlap of the risk loci with underlying biological pathways. Finally, we will discuss how these pathways can be used for therapeutic targeting and how this can help pave the way towards 'precision medicine'.
Part I-Identifying additional common risk variants for inflammatory bowel disease
In Chapter 2 we aimed to identify additional CD risk genes. We hypothesized that part of the genetic risk loci is probably partly hidden among signals discarded by the multiple testing correction needed in the analysis of GWA studies. We prioritized 10
SNPs that are influencing gene-expression of nearby genes (cis-eQTL SNPs) and tested the SNPs for association with CD in two independent cohorts of Dutch CD patients (1539) and healthy controls (2648).
In Chapter 3 we followed up the identification of three genes that were associated to UC in a GWAS study performed in the UK IBD Genetics Consortium. Here we analyse rs6017342 (HNF4-α), rs1728785 (CDH1), and rs6949033 (LAMB1) in a independent Dutch cohort of 821 UC patients and 1260 healthy controls.
Part II-Identification and exploring the role of rare variants in complex diseases
Chapter 4 aims to investigate the contribution of rare, large effect genetic variants to UC susceptibility. We performed a deep pooled targeted resequencing study of 122 UC genes in 790 Dutch UC patients. The Genome of the Netherlands project provided sequence data of 500 healthy controls. After an extensive quality control, follow-up genotyping of German UC cases and 3576 general-population-based German controls.
In chapter 5 we investigated the contribution of rare variants in PSC. We genotyped a large international cohort of 1,243 PSC cases and 10,038 population-matched controls using the Illumina Exome array (Illumina, Inc., San Diego, CA). Association analyses revealed 90 rare genetic loci associated with PSC. Exome array results were validated using the same samples as used in the discovery stage. The replication phase is yet on going, we will replicate 87 variants in four independent cohorts of 2401 PSC cases and 5088 population matched healthy controls.
Part III-The translation of genetic variants into clinical practice
In Chapter 6 we aim to validate the Montreal classification system for CD and UC.
We selected 20 de-identified medical records with an appropriate representation of the IBD sub phenotypes. 30 observers scored the records; the observers had different professions (gastroenterologist specialist in IBD, gastroenterologist in training and IBDnurses) and experience level with IBD patient care.
Chapter 7 aims to identify disease-modifying genes associated with recurrent fibrostenotic CD. Multiple genetic variants are associated with susceptibility for CD, but little is known about genes influencing CD behaviour. We performed a within-cases analysis comparing "extreme phenotypes" using a genome-wide approach (166, 251 SNPs) in two independent case-control cohorts totalling 322 fibrostenotic and 619 purely inflammatory (non-penetrating/non-fistulising) CD cases.
After the identification of a disease-modifying gene, we performed expression analysis of genes in the Transforming Growth Factor-beta (Tgf-β) pathway in human resected tissue of CD patients.
Chapter 8 provides an overview of the results of the studies and future perspectives discussed.
